Streetbeat News

Stock Prices

MELI

Wealthy investors have taken a bearish stance on MercadoLibre (NASDAQ:MELI), as indicated by 47 uncommon options trades detected by Benzinga's options scanner. The sentiment is split with 29% bullish and 38% bearish. The major market movers are focusing on a price band between $480.0 and $2140.0 for MercadoLibre. The stock is currently trading at $1835.63, up by 3.36%, with RSI indicators suggesting it may be approaching overbought territory. Analysts have given it an average target price of $2175.0.

Portfolio Pulse from Benzinga Insights

August 06, 2024 | 7:16 pm

HON

Financial giants have shown a bullish trend in Honeywell Intl (NASDAQ:HON) options trading, with significant trades indicating a price target range of $180 to $210. Analysts have set an average price target of $216.33, with the stock currently priced at $201.0. The next earnings report is expected in 79 days.

Portfolio Pulse from Benzinga Insights

August 06, 2024 | 7:15 pm

KLG

WK Kellogg shares are trading lower after the company reported worse-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 7:15 pm

TNDM

Tandem Diabetes Care shares are trading higher following the company's better-than-expected Q2 earnings report and strong guidance issued last week.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 7:14 pm

DK

Delek US shares are trading lower following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 7:12 pm

BRBR

BellRing Brands shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 guidance.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 7:12 pm

PRAA

PRA Group shares are trading lower following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 7:08 pm

VPG

Vishay Precision Group shares are trading lower after the company reported worse-than-expected Q2 financial results and issued Q3 revenue guidance slightly below estimates.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 7:07 pm

BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has announced a strategic update focusing its Roctavian business on the U.S., Germany, and Italy, where the treatment is approved and reimbursed. The company plans to reduce annual Roctavian expenses to $60 million by 2025 and expects the treatment to be profitable by the end of that year. BioMarin reported strong Q2 results with an adjusted EPS of $0.96, beating the consensus of $0.35, and sales of $712.03 million, driven by Voxzogo and Naglazyme. The company raised its 2024 revenue guidance to $2.75-$2.825 billion and adjusted EPS guidance to $3.10-$3.25. William Blair maintains an Outperform rating on the stock.

Portfolio Pulse from Vandana Singh

August 06, 2024 | 7:06 pm

ANIP

ANI Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 guidance.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 7:04 pm